Tecentriq joins Merck & CO’s Keytruda (pembrolizumab) and BMS’s Opdivin (nivolumab) as the “checkpoint inhibitor” drugs on the market.While Keytruda is also approved for initial lung cancer treatment in some patients, ongoing studies in lung cancer and others could make Tecentriq competitive in the market of first-line treatment of NSCLC.

 

https://www.biopharma-reporter.com/Article/2018/05/09/Roche-s-immunotherapy-combo-receives-FDA-priority-review?utm_source=newsletter_daily&utm_medium=email&utm_campaign=GIN_OSPd&c=B5LaTvdHM6BUM2NtatkRZsJavVaCzjhi&p2=